COVID-19. Novel Cronavirus Disease (COVID-19)
Conditions
Interventions
Intervention 1: Intervention group: In the intervention group, participants will receive Dinvl sublingual tablets 399±5 mg containing 43.5 mg of herbal powder made by Zahravi Pharmaceutical Company
Sponsors
Zahravi Pharmaceutical Company
Eligibility
Sex/Gender
All
Age
15 Years to No maximum
Inclusion criteria
Inclusion criteria: COVID-19 patients aged 15 years and older who newly admitted (first day of hospitalization) Having definite COVID-19 disease Obtaining informed consent to participate in the trial Non-participation in another clinical trial simultaneously
Exclusion criteria
Exclusion criteria: Epilepsy Having liver or renal failure according to the patient's statement, physician examination or based on creatinine, SGOT, SGPT, LDH tests. Immunodeficiency (treated with Corticosteroids over 12.5 mg / d Prednisolone for more than two weeks, chemotherapy, malignancies, organ transplants, HIV patients, other viral diseases. Having other infectious diseases according to the diagnosis of the physician and the information of medical record. Pregnancy (according to the patient's statement and examination by a physician). Breastfeeding (according to the patient's statement).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Respiratory Rate. Timepoint: Daily. Method of measurement: Observation.;Oxygen saturation (SpO2). Timepoint: Daily. Method of measurement: Pulse Oximeter.;Serum White Blood Cell count. Timepoint: Before- 14 days after intervention. Method of measurement: Laboratory cell counter.;Serum CRP level. Timepoint: Before- 14 days after intervention. Method of measurement: Biochemical method.;ESR (Erythrocyte Sedimentation Rate). Timepoint: Before- 14 days after intervention. Method of measurement: Checking the sedimentation rate of erythrocytes in a special tube within one hour.;Number of hospitalization days. Timepoint: After intervention. Method of measurement: Questionnaire.;Mortality. Timepoint: Daily. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| The time of absence of dry Cough. Timepoint: Daily. Method of measurement: ?Daily symptom recording questionnaire.;The time of absence of trembling. Timepoint: Daily. Method of measurement: Daily symptom recording questionnaire.;The time of absence of sore throat. Timepoint: Daily. Method of measurement: Daily symptom recording questionnaire.;The time of absence of dry Cough. Timepoint: Daily. Method of measurement: Daily symptom recording questionnaire.;The time of absence of difficulty in breathing or shortness of breath. Timepoint: Daily. Method of measurement: Daily symptom recording questionnaire.;The time of absence of temperature equal to or grater than 37.8 C. Timepoint: Daily. Method of measurement: Daily symptom recording questionnaire.;Body temperature. Timepoint: Daily. Method of measurement: Thermometer.;Side effects. Timepoint: Daily. Method of measurement: Side effects checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJavad Ahmadian Heris
Tabriz University of Medical Sciences
Outcome results
None listed